Prothena Reports Fourth Quarter and Full Year 2019 Financial Results, and Provides Financial Guidance and R&D Update
12 févr. 2020 16h05 HE
|
Prothena Corporation plc
Net cash used in operating and investing activities was $14.6 million in the fourth quarter and $53.5 million for the full year 2019; quarter-end cash and restricted cash position of $378.4 million...
Prothena to Report Fourth Quarter and Full Year 2019 Financial Results and Host Webcast Conference Call on February 12
05 févr. 2020 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, announced today that it will...
Prothena Announces Appointment of Oleg Nodelman to its Board of Directors
05 déc. 2019 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, announced today the appointment of Oleg Nodelman to its Board of...
Prothena Reports Third Quarter 2019 Financial Results and Provides R&D Update
05 nov. 2019 16h05 HE
|
Prothena Corporation plc
Net cash used in operating and investing activities was $9.2 million in the third quarter and $38.9 million for the first nine months of 2019; quarter-end cash and restricted cash position of $393.0...
Prothena to Report Third Quarter 2019 Financial Results on November 5
29 oct. 2019 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical-stage neuroscience company, will announce financial results for the third quarter and first nine...
Prothena Reports Second Quarter 2019 Financial Results and Provides R&D Update
06 août 2019 16h05 HE
|
Prothena Corporation plc
Net cash used in operating and investing activities was $12.2 million in the second quarter and $29.7 million for the first six months of 2019; quarter-end cash and restricted cash position of $402.2...
Prothena to Report Second Quarter 2019 Financial Results on August 6
30 juil. 2019 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, July 30, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical-stage neuroscience company, will announce financial results for the second quarter and first six...
Prothena Announces Appointment of Paula K. Cobb to its Board of Directors
01 juil. 2019 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, July 01, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, announced today the appointment of Paula Cobb to its Board of...
Prothena to Participate in the Jefferies Healthcare Conference
30 mai 2019 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, May 30, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today announced that members of its senior management team will...
Prothena Reports First Quarter 2019 Financial Results and Provides R&D Update
07 mai 2019 16h05 HE
|
Prothena Corporation plc
Net cash used in operating and investing activities was $17.6 million in the first quarter; quarter-end cash and restricted cash position of $414.2 million provides funding to advance neuroscience...